A recurrent homozygous missense DPM3 variant leads to muscle and brain disease

Sara Nagy1,2 | Tracy Lau1 | Shahryar Alavi3 | Ehsan Ghayoor Karimiani4 | Jalal Vallian3 | Bobby G. Ng5 | Samaneh Noroozi Asl6 | Javad Akhondian7 | Amir Bahreini8 | Omid Yaghini9 | Prech Upinyoying10 | Carsten Bonnemann10 | Hudson H. Freeze5 | Vajira H. W. Dissanayake11 | Nirmala D. Sirisena11 | Miriam Schmidts12 | Henry Houlden1 | Andres Moreno-De-Luca13 | Reza Maroofian1

1MRC Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK
2Department of Neurology, University Hospital Basel, University of Basel, Basel, Switzerland
3Division of Genetics, Department of Cellular and Molecular Biology and Microbiology, Faculty of Science and Technology, University of Isfahan, Isfahan, Iran
4Molecular and Clinical Sciences Institute, St. George’s, University of London, London, UK
5Human Genetics Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA
6Pediatrics Endocrinology Department, Mashhad University of Medical Sciences, Mashhad, Iran
7Pediatric Neurology Department, Ghaem hospital, Mashhad University of Medical Sciences, Mashhad, Iran
8Karyogen Medical Genetics Laboratory, Alzahra University, Isfahan, Iran
9Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran
10Neuromuscular and Neurogenetic Disorders of Childhood Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA
11Department of Anatomy, Genetics & Biomedical Informatics, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka
12Department of Pediatrics and Adolescent Medicine, University Hospital Freiburg, Freiburg University Faculty of Medicine, Germany
13Autism & Developmental Medicine Institute, Genomic Medicine Institute, Department of Radiology, Diagnostic Medicine Institute, Danville, Pennsylvania, USA

Correspondence
Reza Maroofian, MRC Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.
Email: reza.maroofian@ucl.ac.uk

Funding information
Deutsche Forschungsgemeinschaft,
Grant/Award Number: SFB 1453; European Research Council; Rocket Fund, Grant/Award Number: R01DK99551; National Institute for Health Research University College London Hospitals Biomedical Research Centre; Medical Research Council, Grant/Award Numbers: 716344, G0601943, MR/S005021/1, MR/S01165X/1

Abstract
Biallelic pathogenic variants in the genes encoding the dolichol-phosphate mannose synthase subunits (DPM) which produce mannosyl donors for glycosylphosphatidylinositol, N-glycan and protein O- and C-mannosylation, are rare causes of congenital disorders of glycosylation. Pathogenic variants in DPM1 and DPM2 are associated with muscle–eye–brain (MEB) disease, whereas DPM3 variants have mostly been reported in patients with isolated muscle disease—dystroglycanopathy. Thus far, only one affected individual with compound heterozygous DPM3 variants presenting with myopathy, mild intellectual disability, seizures, and nonspecific white matter abnormalities (WMA) around the lateral ventricles has been described. Here we present five affected individuals from four unrelated families with global developmental delay/intellectual disability ranging from mild to severe, microcephaly, seizures,
WMA, muscle weakness and variable cardiomyopathy. Exome sequencing of the probands revealed an ultra-rare homozygous pathogenic missense *DPM3* variant NM_018973.4:c.221A>G, p.(Tyr74Cys) which segregated with the phenotype in all families. Haplotype analysis indicated that the variant arose independently in three families. Functional analysis did not reveal any alteration in the N-glycosylation pathway caused by the variant; however, this does not exclude its pathogenicity in the function of the DPM complex and related cellular pathways. This report provides supporting evidence that, besides *DPM1* and *DPM2*, defects in *DPM3* can also lead to a muscle and brain phenotype.

**KEYWORDS**

congenital disorders of glycosylation (CDG), DPM3, dystroglycanopathy, muscle dystrophy, muscle-eye-brain (MEB) disease

---

**1 | INTRODUCTION**

Biallelic variants in DPM subunits 1 and 2 (*DPM1*, MIM 608799; *DPM2*, MIM 615042) are known to be associated with muscle–eye–brain (MEB) disease, while biallelic variants in *DPM3* (MIM 612937) were initially described only in the context of muscle dystrophy and cardiomyopathy. In 2019, Fu et al presented the first patient, a Chinese girl with combined muscle and central nervous system involvement due to compound heterozygous variants in *DPM3*. Here we report three unrelated Iranian families and one from Sri Lanka with five children presenting with congenital muscle weakness, developmental delay (DD)/intellectual disability (ID), and epilepsy due to an ultra-rare homozygous missense *DPM3* variant. Informed consent was obtained from the parents.

**2 | CLINICAL CHARACTERISATION**

**2.1 | Patients 1 and 2**

The proband is a 4-year-old girl from a consanguineous Iranian Turkmen family (Figure 1A, Family 1). She exhibited microcephaly, hypotonia, significant motor and speech delay and failure to thrive. She was able to sit unassisted at the age of 2 years, but never reached the walking milestone. She could not speak more than two words and displayed severe global DD, muscle weakness and muscle atrophy, febrile convulsions and afebrile tonic seizures. She had urinary and bowel incontinence. Blood tests revealed elevated serum transaminases (TA) and creatine kinase (CK) up to 1500 U/L. Her electroencephalogram (EEG) showed scattered sharp waves. Nerve conduction studies were normal; however, myography of the distal and proximal lower limbs showed myopathic changes without signs of acute denervation. Magnetic resonance imaging (MRI) of the brain performed at the age of 2 years showed subcortical and periventricular white matter abnormalities (WMA) most pronounced in the periatrial regions with some of the foci distributed along the axis of medullary veins perpendicular to the body of the lateral ventricles/corpus callosum (Figure 2A–E). Ophthalmologic and cardiologic examinations were normal.

In the same family, the younger brother of the proband showed a similar clinical presentation. His brain MRI performed at the age of 1 year revealed hypomyelination and periventricular WMA (Figure 2F–J).

**2.2 | Patient 3**

The 2.5-years-old daughter of non-consanguineous Persian parents from the same village without a family history of neurological disorders (Figure 1A, Family 2) showed microcephaly, hypotonia, muscle weakness and epilepsy as an infant, delayed motor and speech development, and dysarthria. She reached the walking milestone (with some ataxia) at the age of 2 years and 3 months. Serum CK and TA were increased, and the EEG showed a mildly abnormal background with epileptic discharges. Echocardiography revealed a mildly dilated left ventricle with mildly decreased left ventricular systolic function. There were no signs of eye involvement.

**2.3 | Patient 4**

An adult Persian man born to a consanguineous marriage (Figure 1A, Family 3) presented with DD, ID, motor disability, cardiomyopathy and epilepsy. He had a progressive disease course, became wheelchair-bound and died at the age of 26.

**2.4 | Patient 5**

The proband is a 4-year-old Sri Lankan daughter of non-consanguineous parents. She presented with global DD, recurrent generalised seizures since infancy, muscle weakness, hypotonia and...
microcephaly. She was able to sit unassisted at the age of 3 years, but never arrived at walking. Serum CK and ammonia levels were elevated with 1507 U/L and 53 μmol/L, respectively. The EEG showed changes suggestive of generalised epilepsy, and the myography revealed myopathic features. MRI scan of the brain showed T2/FLAIR hyperintense foci in the subcortical and periventricular WM and globi pallidi, mildly prominent lateral ventricles, WM volume loss and mega cisterna magna. The muscle biopsy confirmed myopathic changes with increased fibre size variability, fibre splitting and intrafascicular fibrosis (Figure 2K–O).

An affected male sibling died at the age of 1 year and 9 months from a similar but more severe condition.
Solo exome sequencing of the affected Iranian individuals and trio exome sequencing of the Sri-Lankan family revealed the same missense variant chr1:g.155140110T>C;NM_018973.4(DPM3):c.221A>G, p.(Tyr74Cys) residing within sizable regions of homozygosity (Figure 1B). However, three distinct haplotypes surrounding the variant were found in these families (Figure 1C). Sanger sequencing segregation analysis showed the variant segregated well within the families (Figure 1E). Only seven carriers were observed in around 1,500,000 alleles aggregated across multiple variant frequency databases. The ultra-rare variant located within one of the transmembrane domains, affecting a highly conserved residue among vertebrates (CADD: 32, GERP: 2.66, REVEL: 0.9049) (Figure 1D,F). In addition, multiple in silico tools predict the variant to being deleterious (SIFT: 0.04, PolyPhen: 0.993, Mutation Taster: 1, Provean: −5.28). The variant was classified as pathogenic according to the American College of Medical Genetics and Genomics and the Association for Molecular Pathology standards and guidelines for the interpretation of sequence variants.6

To assess the potential pathogenic effects of the p.(Tyr74Cys) variant on DPM3 function, patient derived fibroblasts were used to analyse lipid-linked oligosaccharide (LLO) synthesis. Metabolic labelling of control and patient fibroblasts with 3H-mannose followed by LLO extraction showed no significant difference between control and patient (Figure S1). We also attempted to analyse the potential effects of the variant on alpha-dystroglycan (alphaDG) using the glycoconjugate specific antibody, IIH6. However, we were unable to detect alphaDG using IIH6 in patient or control fibroblast samples (Figure S2). This is likely due to the low expression level of alphaDG in fibroblasts.

3 | GENETIC FINDINGS

Solo exome sequencing of the affected Iranian individuals and trio exome sequencing of the Sri-Lankan family revealed the same missense variant chr1:g.155140110T>C;NM_018973.4(DPM3):c.221A>G, p.(Tyr74Cys) residing within sizable regions of homozygosity (Figure 1B). However, three distinct haplotypes surrounding the variant were found in these families (Figure 1C). Sanger sequencing segregation analysis showed the variant segregated well within the families (Figure 1E). Only seven carriers were observed in around 1,500,000 alleles aggregated across multiple variant frequency databases. The ultra-rare variant located within one of the transmembrane domains, affecting a highly conserved residue among vertebrates (CADD: 32, GERP: 2.66, REVEL: 0.9049) (Figure 1D,F). In addition, multiple in silico tools predict the variant to being deleterious (SIFT: 0.04, PolyPhen: 0.993, Mutation Taster: 1, Provean: −5.28). The variant was classified as pathogenic according to the American College of Medical Genetics and Genomics and the Association for Molecular Pathology standards and guidelines for the interpretation of sequence variants.6

4 | DISCUSSION

Congenital muscle dystrophies caused by DPM variants are autosomal recessive disorders belonging to the group of dystrophy-dystroglycanopathies with limb girdle involvement. In the recent years, an increasing number of variants have been described with expansion of the phenotypes associated with DPM1, DPM2 and DPM3. Affected individuals with DPM variants are, however, still rare,
TABLE 1  clinical features of affected individuals with DPM3-related disorder

<table>
<thead>
<tr>
<th></th>
<th>F1—Case 1</th>
<th>F1—Case 2</th>
<th>F2—Case 3</th>
<th>F3—Case 4a</th>
<th>F4—Case 5</th>
<th>Case 6 (Fu et al, 2019)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age</strong></td>
<td>4y</td>
<td>2y</td>
<td>2.5y</td>
<td>25y</td>
<td>4y</td>
<td>8y</td>
</tr>
<tr>
<td><strong>Sex</strong></td>
<td>f</td>
<td>m</td>
<td>f</td>
<td>m</td>
<td>f</td>
<td>f</td>
</tr>
<tr>
<td><strong>Consanguinity</strong></td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td><strong>Peripheral nervous system involvement</strong></td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td><strong>Muscle weakness</strong></td>
<td>+</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td><strong>Muscle atrophy</strong></td>
<td>+</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>+</td>
<td>na</td>
</tr>
<tr>
<td><strong>Muscle hypotonia</strong></td>
<td>+</td>
<td>na</td>
<td>+</td>
<td>–</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td><strong>Central nervous system involvement</strong></td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td><strong>Developmental delay</strong></td>
<td>+ (Severe)</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td><strong>Intellectual disability</strong></td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>+</td>
<td>na</td>
<td>+ (Mild)</td>
</tr>
<tr>
<td><strong>Epilepsy</strong></td>
<td>+</td>
<td>na</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>(Generalised)</td>
</tr>
<tr>
<td><strong>Gait ataxia</strong></td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td><strong>Autonomic involvement</strong></td>
<td>+ (Bowel and urinary incontinence)</td>
<td>na</td>
<td>+</td>
<td>na</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td><strong>Growth and development</strong></td>
<td>&lt;3rd %ile</td>
<td>na</td>
<td>Normal</td>
<td>na</td>
<td>&lt;3rd %ile</td>
<td>na</td>
</tr>
<tr>
<td><strong>Weight at last visit</strong></td>
<td>Normal</td>
<td>na</td>
<td>Normal</td>
<td>na</td>
<td>&lt;3rd %ile</td>
<td>na</td>
</tr>
<tr>
<td><strong>Height at last visit</strong></td>
<td>Normal</td>
<td>na</td>
<td>Normal</td>
<td>na</td>
<td>&lt;3rd %ile</td>
<td>na</td>
</tr>
<tr>
<td><strong>Microcephaly</strong></td>
<td>+</td>
<td>+</td>
<td>&lt;15th %ile</td>
<td>na</td>
<td>&lt;3rd %ile</td>
<td>na</td>
</tr>
<tr>
<td><strong>Ability to walk at last visit</strong></td>
<td>na</td>
<td>na</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td><strong>Brain MRI</strong></td>
<td>Patchy and confluent WMA in the subcortical and periventricular regions, mild WM volume loss</td>
<td>Hypomyelination, WMA in the periventricular region, mildly prominent subarachnoid spaces overlying the frontal and temporal lobes</td>
<td>na</td>
<td>na</td>
<td>T2/FLAIR hyperintense foci in the subcortical and periventricular WM and globi pallidi, mildly prominent lateral ventricles, WM volume loss, mega cisterna magna</td>
<td>WMA around lateral ventricles</td>
</tr>
<tr>
<td><strong>Elevated CK</strong></td>
<td>+</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td><strong>Electromyography</strong></td>
<td>Myopathic changes</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>+</td>
<td>Myopathic changes</td>
</tr>
<tr>
<td><strong>Cardiac assessment</strong></td>
<td>Normal</td>
<td>na</td>
<td>Cardiomyopathy</td>
<td>Cardiomyopathy</td>
<td>Normal</td>
<td>Normal</td>
</tr>
<tr>
<td><strong>Ophthalmic assessment</strong></td>
<td>Normal</td>
<td>normal</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td><strong>Muscle biopsy</strong></td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>Myopathic changes</td>
<td>Mild non-specific Myopathic changes</td>
</tr>
</tbody>
</table>

(Continues)
and thus far, only 21 patients have been reported with a pathogenic or likely pathogenic variant in one of the three subunit coding genes.\textsuperscript{10}

Affected individuals with DPM1 and DPM2 variants frequently show central nervous system involvement,\textsuperscript{1} thus, one would expect a similar phenotype in DPM3. Nevertheless, only one individual has been reported with DPM3-related dystroglycanopathy and WMA on brain MRI,\textsuperscript{7} and Lefeber et al. reported stroke-like episodes in a patient with DPM3-related muscle dystrophy.\textsuperscript{2} Hereby we describe five patients with a genetically confirmed homozygous variant in DPM3, presenting with muscle involvement along with WMA, DD/ID, and epilepsy. Interestingly, disease severity was variable and affected individuals exhibited distinctive features despite carrying the identical missense variant across the families (Table 1).

Although only one patient underwent muscle biopsy, the presence of severe muscle weakness and hypotonia suggests an underlying congenital muscle dystrophy, and in two patients, myopathic changes were confirmed by myography. Additionally, two patients presented with cardiomyopathy. The brain MRI of the patients showed periventricular WMA similar to the patient of Fu et al.,\textsuperscript{7} however, we also identified WMA in the subcortical region and WM volume loss. Thus, we conclude this new and pathogenic variant in DPM3 can lead to congenital muscle and brain disease.

The exact pathogenicity of the disorder is not well understood. Glycosylation involves the addition of glycans to proteins and lipids through one of the eight major enzymatic pathways described in mammals.\textsuperscript{10,11} The DPM complex plays a role in four of these pathways.\textsuperscript{2} While DPM1 is the catalytic subunit localised in the cytoplasm, DPM2 and DPM3 subunits anchor DPM1 to the endoplasmic reticulum membrane. The coiled-coil domain of DPM3 is responsible for the anchoring of DPM1, whereas its N-terminal transmembrane domain is linked to DPM2.\textsuperscript{2,11,12} Interestingly, the homozygous p.(Tyr74Cys) variant is located on a transmembrane domain next to p.(Pro72Ala) variant which was identified as compound het with p.(Leu115Ter) in the girl with muscle and brain presentation.\textsuperscript{7} However, the biochemical assay could not detect any changes in the N-glycosylation pathway, which correlates with previous findings stating that the transmembrane domain is not necessary for the enzymatic activity of the complex.\textsuperscript{12} In contrast, the highly conserved coiled-coil region was shown to be required for the enzymatic process, and variant in this domain was associated with reduced O-mannosylation of alpha-dystroglycan due to reduced binding capacity of DPM3 for DPM1.\textsuperscript{2} The finding that the variant we identified does not seem to disturb glycosylation points to potentially other mechanisms of pathogenicity. The haplotype analysis suggests that the DPM3 variant most likely recurred in at least three families which was not unexpected given the different ethnicities of the families. This finding along with consistent clinical and genetic data across four independent families provides additional support that p.Tyr74 residue is fundamental for proper function of DPM3.

In this study, we consolidate the association of DPM3 variants with brain-muscle phenotype and further delineate the molecular and clinical spectrum associated with this new ultra-rare congenital disorder of glycosylation.
AUTHOR CONTRIBUTIONS
Sara Nagy reviewed the clinical data and drafted the manuscript. Tracy Lau, Vajira H.W. Dissanayake, and Nirmala D. Sirisena reviewed the genetic data. Ehsan Ghayoor Karimiani, Jalal Vallian, Shahryar Alavi, Samaneh Norooz Asl, Javad Akhondian, Amir Bahreini, Omid Yaghini, Vajira H.W. Dissanayake, and Nirmala D. Sirisena provided clinical information. Miriam Schmidts, Jalal Vallian, Shahryar Alavi, Prech Uapinyyoyn and Carsten Bonnemann performed genetic testing. Bobby G. Ng and Hudson H. Freeze performed the functional assay. Andres Moreno-De-Luca reviewed the imaging data. Henry Houlden edited the manuscript. Reza Maroofian supervised the project and edited the manuscript.

ACKNOWLEDGEMENTS
Henry Houlden was funded by the MRC (MR/S01165X/1, MR/S005021/1, G0601943), the National Institute for Health Research University College London Hospitals Biomedical Research Centre. Hudson H. Freeze acknowledges the support of the Rocket Fund and R01DK99551. Miriam Schmidts acknowledges funding from the European Research Council ERC (ERC starting grant TREATCilia, grant agreement no. 716344), and the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)—Project-ID 431984000—SFB 1453.

CONFLICT OF INTEREST
The authors have no conflict of interest.

DATA AVAILABILITY STATEMENT
Anonymized data from participants will be available on request.

ETHICS STATEMENT
All participated families provided informed consent. Procedures were reviewed and approved by the appropriate institutional review committee.

ORCID
Shahryar Alavi https://orcid.org/0000-0002-3484-3423
Nirmala D. Sirisena https://orcid.org/0000-0003-0994-6954
Andres Moreno-De-Luca https://orcid.org/0000-0002-2732-4043

REFERENCES

SUPPORTING INFORMATION
Additional supporting information can be found online in the Supporting Information section at the end of this article.